Bio Pharma Dive
SEPTEMBER 7, 2023
Fresh off a Series C fundraise, Kriya has acquired the privately held Tramotane Therapeutics and its preclinical candidate for the widely prevalent liver disease.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Veracyte has announced a partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
SEPTEMBER 7, 2023
The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.
Pharmaceutical Technology
SEPTEMBER 7, 2023
The country returns to the EU’s research programme after a Brexit-related absence and questions surrounding its re-entry prospects.
Bio Pharma Dive
SEPTEMBER 7, 2023
The trial found two higher doses of Alynlam’s RNAi therapy lowered blood pressure better than placebo. But analysts say results from a different study will be more important for the drug’s future.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Cidara will also receive $7m in milestone payments for the drug-Fc conjugate as part of the Election to Proceed from Janssen.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Nimbus plans to use these funds to aid new drug discovery efforts and plans to continue existing programs in oncology and metabolic disorders.
Bio Pharma Dive
SEPTEMBER 7, 2023
The drugmaker said it still believes the U.S. government’s price negotiation powers are unconstitutional, but is pulling back a lawsuit it filed in July.
Pharmaceutical Technology
SEPTEMBER 7, 2023
IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).
Pharma Times
SEPTEMBER 7, 2023
The trial analyses the impact of its ‘Neuro-Cells’ among patients with traumatic spinal cord injuries - News - PharmaTimes
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
SEPTEMBER 7, 2023
Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.
Fierce Pharma
SEPTEMBER 7, 2023
Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Novo Nordisk has entered a collaboration with The Broad Institute to detect drug targets for Type 2 diabetes and cardiometabolic diseases.
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
SEPTEMBER 7, 2023
Patient information on the Janssen CarePath was accessed, but the true extent of the breach is still unknown.
Rethinking Clinical Trials
SEPTEMBER 7, 2023
sub-title space Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Pharma Times
SEPTEMBER 7, 2023
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact - News - PharmaTimes
pharmaphorum
SEPTEMBER 7, 2023
In today’s episode, sponsored by Veeva, we’ll hear a roundtable discussion on this fascinating topic featuring Victoria Serra Gittermann, European customer experience lead at Veeva Systems and Sebastian Noel, Veeva’s director of multichannel strategy – moderating a discussion with two executives with first-hand experience leading this change: Andy Eeckhout, global head of CRM and digital solutions at Advanz Pharma and Mokhtar Elsayed, head of global go to market commercial transformation at Sano
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
SEPTEMBER 7, 2023
Los Angeles Lakers and Spain’s basketball legend Pau Gasol is investing in artificial intelligence (AI) company Idoven , which is developing an AI-powered cardiology service platform. The platform is designed to support cardiologists and other clinicians in the identification, triage and diagnosis of patients. The company’s goal is to develop an AI-based cardiology platform that has increased the ability to identify and diagnose cardiovascular diseases on a large scale.
ProRelix Research
SEPTEMBER 7, 2023
Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.
XTalks
SEPTEMBER 7, 2023
For a significant portion of the world’s population, baking is punctuated by the pain and discomfort of food intolerances. Lactose stands out as a particularly pesky ingredient in this regard. In this episode of the Xtalks Food Podcast, Sydney talks about Intoleran, a beacon of hope for those troubled by lactose. The Dutch brand, founded by Harmen Treep in 2008, recognized the immense gap in the market and created a line of lactase enzyme supplements tailored to cater to the lactose-intolerant c
Fierce Pharma
SEPTEMBER 7, 2023
University of Pennsylvania spinout BlueWhale Bio has surfaced on a mission to smash bottlenecks in cell and gene therapy manufacturing. | Cell therapy manufacturer BlueWhale Bio uncloaked Thursday with news it has raised $18 million in seed financing. The funding round was led by Danaher Corporation.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Outsourcing Pharma
SEPTEMBER 7, 2023
The UK organ-on-a-chip (OOC) company CN Bio has teamed up with LifeNet Health LifeSciences to gain access to the non-profit tissue bankâs validated human cells for use in organ models for life sciences research.
Fierce Pharma
SEPTEMBER 7, 2023
It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. | Roche may not receive the FDA's decision on a subcutaneous version of its cancer immunotherapy Tecentriq on time thanks to the agency's requirement for changes to the drug's manufacturing process.
pharmaphorum
SEPTEMBER 7, 2023
The importance of collaboration in tackling the ethical concerns of cell and gene therapy Mike.
Fierce Pharma
SEPTEMBER 7, 2023
Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag. | J&J’s Janssen has decided to stop a phase 3 trial for a high dose of Opsumit in a subtype of pulmonary hypertension. With the flop, J&J loses a chance to challenge Bayer's Adempas.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
SEPTEMBER 7, 2023
Five takeaways from the CAR-TCR cell therapy conference Mike.
Fierce Pharma
SEPTEMBER 7, 2023
Thanks to a contract manufacturing deal with Takeda gone awry, AbbVie appears to be in line to receive hundreds of millions of dollars in damages. | The Delaware Court of Chancery sided with AbbVie in the damages portion of the case, granting the drugmaker nearly all of the $480.6 million it was seeking over a botched supply agreement for Lupron.
pharmaphorum
SEPTEMBER 7, 2023
Improving access to brand planning tools through modular offerings Mike.
Fierce Pharma
SEPTEMBER 7, 2023
PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get | PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get filled.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
280 
Let's personalize your content